Literature DB >> 25853798

Influence of Immunogenicity of Allogeneic Bone Marrow Mesenchymal Stem Cells on Bone Tissue Engineering.

JingGuo Wu1, Qian Wang, Xin Fu, XiaoWei Wu, CongMin Gu, JianHai Bi, FangNan Xie, Ning Kang, Xia Liu, Li Yan, YiLin Cao, Ran Xiao.   

Abstract

Allogeneic bone marrow mesenchymal stem cell (allo-BMSC)-based tissue-engineered bone (TEB) has great potential for bone defect repair. However, the immunogenicities and biological roles of allo-BMSCs are still controversial. In this study, we established an animal model of critical-sized mandibular defect in beagle dogs and compared the repairing effects of allo-BMSC-based TEB with autogenic BMSC (auto-BMSC)-based TEB without the administration of immunosuppressants. During the first 2 weeks postimplantation, a transient immune response in the allo-BMSC group was detected with an increase in proinflammation cytokines TNF-α, IFN-γ, and IL-2, a declination of anti-inflammation cytokine IL-10, and an increase in percentages of CD4(+) and CD8(+) T-cell subsets in peripheral blood. Nevertheless, there was no significant difference in bone union achievement, bone mineral density, and biomechanical properties between the two groups at 12 and 24 weeks postimplantation. Further subcutaneous implantation of allo-BMSCs/scaffold also exhibited the similar transient immune responses in the first 2 weeks postimplantation but followed by a decreased bone formation at 4 and 8 weeks postimplantation. These findings indicate that allo-BMSCs can induce a transient immunoreaction, which may temporally delay the osteogenesis of allo-BMSC/scaffold complex in early stage of in vivo implantation, whereas the long-term engineered bone formation was not affected.

Entities:  

Mesh:

Year:  2015        PMID: 25853798     DOI: 10.3727/096368915X687967

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  7 in total

1.  miR-148b-3p, miR-337-5p and miR-423-5p expression in alveolar ridge atrophy and their roles in the proliferation and apoptosis of OMMSCs.

Authors:  Sefei Yang; Jun Guo; Lei Zhou; Helin Xing; Xianli Wang; Chaofang Dong
Journal:  Exp Ther Med       Date:  2018-10-11       Impact factor: 2.447

2.  Bone marrow mesenchymal stem cells inhibit dendritic cells differentiation and maturation by microRNA-23b.

Authors:  Jingguo Wu; Chengbo Ji; Feifei Cao; Hongfen Lui; Bo Xia; Lanping Wang
Journal:  Biosci Rep       Date:  2017-04-20       Impact factor: 3.840

3.  Differentiation of Human Amniotic Mesenchymal Stem Cells into Human Anterior Cruciate Ligament Fibroblast Cells by In Vitro Coculture.

Authors:  Yuwan Li; Ziming Liu; Ying Jin; Xizhong Zhu; Shengmin Wang; Jibin Yang; Youliang Ren; Qiang Fu; Huazhang Xiong; Gang Zou; Yi Liu
Journal:  Biomed Res Int       Date:  2017-09-20       Impact factor: 3.411

4.  Prevascularization promotes endogenous cell-mediated angiogenesis by upregulating the expression of fibrinogen and connective tissue growth factor in tissue-engineered bone grafts.

Authors:  Pengzhen Cheng; Donglin Li; Yi Gao; Tianqing Cao; Huijie Jiang; Jimeng Wang; Junqin Li; Shuaishuai Zhang; Yue Song; Bin Liu; Chunmei Wang; Liu Yang; Guoxian Pei
Journal:  Stem Cell Res Ther       Date:  2018-07-04       Impact factor: 6.832

5.  Autologous Mesenchymal Stroma Cells Are Superior to Allogeneic Ones in Bone Defect Regeneration.

Authors:  Anna E Rapp; Ronny Bindl; Annika Erbacher; Anne Kruchen; Markus Rojewski; Hubert Schrezenmeier; Ingo Müller; Anita Ignatius
Journal:  Int J Mol Sci       Date:  2018-08-25       Impact factor: 5.923

Review 6.  Future Perspectives on the Role of Stem Cells and Extracellular Vesicles in Vascular Tissue Regeneration.

Authors:  Eoghan M Cunnane; Justin S Weinbaum; Fergal J O'Brien; David A Vorp
Journal:  Front Cardiovasc Med       Date:  2018-07-03

7.  Allogeneic Bone-Marrow Mesenchymal Stem Cell with Moldable Cryogel for Craniofacial Bone Regeneration.

Authors:  Cheng-Feng Chu; Shih-Hsuan Mao; Victor Bong-Hang Shyu; Chih-Hao Chen; Chien-Tzung Chen
Journal:  J Pers Med       Date:  2021-12-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.